BMG LABTECH and InvivoSciences Initiate Market Collaboration to Accelerate Drug Discovery in Engineered 3D Tissues

19 Nov 2013
Share
BMG LABTECH, a leading developer and manufacturer of microplate reader instrumentation, has announced a strategic collaboration with InvivoSciences, a leader in stem cell tissue engineering relating to drug discovery. The collaboration aims to market time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies.


Employing an automated system, 3D heart tissues are fabricated with cardiomyocytes derived from human induced pluripotent stem cells. The ultra- sensitive plate reader, CLARIOstar®, will analyze rapid beat-to-beat changes (up to 50 Hz) in the fluorescence intensities of dyes that indicate physiological states in engineered 3D heart tissue after drug/compound application.

Ayla Annac, Co-founder and CEO of InvivoSciences commented, "We are especially proud and pleased to establish a long-term relationship with the leading developer and internationally-recognized manufacture of microplate readers, BMG LABTECH."

"InvivoSciences has established themselves as a leader in engineered 3D tissues using pluripotent stem cells," said E.J. Dell, Ph.D., International Marketing Director of BMG LABTECH. "We are pleased to partner with them to create a drug discovery platform that is biologically more relevant to researchers."

In recognition of this partnership InvivoSciences will be sponsoring a workshop during Cell Based Assays Summit in Munich Germany, December 2nd – 4th 2013. BMG LABTECH will also have a short presentation at the workshop to discuss the applications of microplate readers in cell and tissue based assays.

Furthermore, both BMG LABTECH and InvivoSciences will be presenting a workshop tutorial at the Society for Laboratory Automation and Screening (SLAS) convention in San Diego, CA, January 20th 2014.

Request Info


Company website

BMG LABTECH
profile photo

Liam McNair
Content Editor